Novavax Inc. (NVAX)
NVAX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1000694/000100069426000007/0001000694-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NVAX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001000694 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.1B |
| Net income | $440.3M |
| Operating income | $452.8M |
| Net margin | 39.2% |
| Operating margin | 40.3% |
| Revenue growth | +64.7% |
| Cash | $240.6M |
| Total assets | $1.2B |
| P/E (computed) | 3.0× |
| P/S (computed) | 1.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $222.5M cash; operating cash flow -$59.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 165,009,009 (2026-10-31); 162,498,995 a year earlier; 118,790,222 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Tysons, Virginia, United States | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $68.3M | -$31.4M | -$94.2M | $222.5M | $292.1M | $411.6M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $56.7M | -$53.4M | -$72.8M | $191.5M | $291.5M | $413.8M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $139.5M | -$9.5M | -$32.4M | $228.4M | $291.0M | $596.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $147.1M | $17.5M | -$39.5M | $240.6M | $244.2M | $1.1B | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $70.4M | -$202.4M | $107.8M | $268.0M | No debt tags | $1.1B | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $239.2M | $106.5M | -$127.5M | $253.7M | No debt tags | $1.1B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $666.7M | $518.6M | -$185.5M | $263.3M | No debt tags | $1.3B | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $88.3M | -$81.0M | -$173.2M | $530.2M | $169.7M | $682.2M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-08-08 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.9% |
| 1 month | -33.5% |
| 3 months | +4.8% |
| Year to date | +26.9% |
| 1 year | +20.8% |
| From 52-week high | -33.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TSHA | Taysha Gene Therapies Inc. | $4.06 | -0.98% | $1.3B |
| LYCA | Lycia Therapeutics Inc. | $28.61 | -8.30% | $1.5B |
| IMCR | Immunocore Holdings plc | $28.88 | -3.54% | $1.5B |
| VOR | Vor Biopharma Inc. | $18.97 | -2.32% | $1.2B |
| INBX | Inhibrx Biosciences Inc. | $77.66 | -6.77% | $1.1B |
| MESO | Mesoblast Limited | $12.45 | -6.18% | $1.6B |
| VIR | Vir Biotechnology Inc. | $9.58 | -3.82% | $1.6B |
| ALVO | Alvotech | $4.41 | +5.13% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier